| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $25.0M | — | -5.7% |
| SG&A Expense | $6.1M | — | +31.3% |
| Operating Income | -$31.1M | — | +0.2% |
| Net Income | -$29.6M | — | -1.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $177.9M | +108.3% | +742.2% |
| Current Assets | $205.0M | +44.3% | +23.9% |
| Total Assets | $208.5M | +43.0% | +22.5% |
| Current Liabilities | $47.8M | -26.3% | +115.8% |
| Total Liabilities | $50.5M | -25.5% | +94.9% |
| Stockholders' Equity | $158.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$44.6M | — | -68.1% |
| Capital Expenditures | $49K | — | +0.0% |
| Investing Cash Flow | $29.0M | — | +100.7% |
| Financing Cash Flow | $108.1M | — | — |
| Free Cash Flow | -$44.7M | — | -68.0% |
| +9.5% |